Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer (Q40384759)

20 September 2017

Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer (English)

1 reference

20 September 2017

glycogen storage disease

1 reference

5

1 reference

20 September 2017

Ghosh A

1

1 reference

20 September 2017

Allamarvdasht M

2

1 reference

20 September 2017

Pan CJ

3

1 reference

20 September 2017

Sun MS

4

1 reference

20 September 2017

Byrne BJ

6

1 reference

20 September 2017

Chou JY

7

1 reference

20 September 2017

1 February 2006

1 reference

20 September 2017

1 reference

20 September 2017

13

1 reference

20 September 2017

321-329

1 reference

20 September 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.gt.3302650

20 September 2017

0 references

cites work

Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Mutations in the glucose-6-phosphatase gene that cause glycogen storage disease type 1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Ontogeny of the murine glucose-6-phosphatase system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Transmembrane topology of glucose-6-phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

The catalytic center of glucose-6-phosphatase. HIS176 is the nucleophile forming the phosphohistidine-enzyme intermediate during catalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Inactivation of the glucose 6-phosphate transporter causes glycogen storage disease type 1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Glucose-6-phosphatase dependent substrate transport in the glycogen storage disease type-1a mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Correction of glycogen storage disease type 1a in a mouse model by gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Integration of adeno-associated virus (AAV) and recombinant AAV vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Evaluation of risks related to the use of adeno-associated virus-based vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Adenovirus vectors for gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Adenovirus-mediated gene transfer to liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Renal function: the Cinderella of cardiovascular risk profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Generation and characterization of chimeric recombinant AAV vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

A glucose-6-phosphate hydrolase, widely expressed outside the liver, can explain age-dependent resolution of hypoglycemia in glycogen storage disease type Ia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Identification and characterisation of a new human glucose-6-phosphatase isoform

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Glucose-6-phosphatase flux in vitro is increased in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Effect of acute diabetes on rat hepatic glucose-6-phosphatase activity and its messenger RNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

High levels of glucose-6-phosphatase gene and protein expression reflect an adaptive response in proliferating liver and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Novel tools for production and purification of recombinant adenoassociated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38- subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Production and purification of recombinant adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

Continuous nocturnal intragastric feeding for management of type 1 glycogen-storage disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

inferred from DOI database lookup

7 January 2021

based on heuristic

Cornstarch therapy in type I glycogen-storage disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302650

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.GT.3302650

1 reference

Dimensions Publication ID

20 September 2017

0 references

1 reference